$38 Million Verdict for Child Born with Spina Bifida After In-Utero Depakote Exposure
Won by Williams Hart & Boundas.
A St. Louis jury returned a $38 million verdict against Abbott Laboratories for failing to adequately warn patients and physicians that Depakote, taken during pregnancy to control epilepsy, could cause severe birth defects including spina bifida.
What happened
Depakote, Abbott Laboratories' anti-seizure drug, carries serious risks when taken during pregnancy. The drug's active compound can cross the placenta and interfere with fetal development, raising the likelihood of neural-tube defects. For years, critics argued Abbott did not communicate those risks clearly enough to prescribing physicians or to patients of childbearing age.
Maddison Schmidt was born with spina bifida, a condition in which the spinal column does not fully close, after her birth mother took Depakote during pregnancy to manage epilepsy. The defect caused lasting physical impairment. Maddison's adoptive family, Garry and Tammy Schmidt, filed suit against Abbott in Missouri state court, alleging the company's labeling and warnings were inadequate and that Abbott prioritized sales over patient safety.
The case went to a jury in the City of St. Louis in May 2015. Attorneys from Williams Kherkher Hart Boundas, including John Boundas and Sejal Brahmbhatt, served as lead plaintiff's counsel alongside co-counsel from Bartimus Frickleton Robertson and other firms. The trial team presented evidence that Abbott knew of the drug's teratogenic potential and did not take sufficient steps to reduce the risk of prescribing to pregnant patients.
The jury found for the plaintiff and returned a verdict of $15 million in compensatory damages and $23 million in punitive damages, totaling $38 million. It was the first jury verdict Abbott had lost in the Depakote birth-defects litigation, which at that point included more than 800 pending lawsuits. A juror told reporters afterward that the jury felt certain things about Abbott's handling of the drug needed to change.
Abbott appealed. In 2017, the Missouri Supreme Court affirmed the circuit court's judgment in full, holding that Abbott had received a fair trial and declining to disturb the verdict. The $38 million award was not reduced. By the time of the appeal, Abbott's pharmaceutical spinoff AbbVie had assumed responsibility for the Depakote litigation portfolio.
Sources
This account is drawn from contemporaneous public reporting and the court record.
More proven verdicts from Williams Hart & Boundas
All Williams Hart & Boundas proven verdicts →John Eddie Williams, Jr. served as one of five private attorneys retained by the State of Texas to sue the major tobacco companies, producing a $15.3 billion settlement in January 1998, the largest single-case settlement in U.S. history at the time.
A St. Louis jury awarded $46.5 million to three plaintiffs who developed non-Hodgkin lymphoma after PCB exposure, delivering the first plaintiff verdict of its kind against Monsanto in the city.
A federal jury in East St. Louis found in June 2017 that Abbott Laboratories failed to warn a prescribing doctor about the risk of severe birth defects from Depakote. It awarded $15 million in compensatory damages to a 10-year-old boy born with spina bifida after his mother took the drug during pregnancy. The jury declined to award punitive damages.
Jim Hart won a $12.45 million jury verdict for a Houston couple severely injured when a New Prime tractor-trailer rear-ended their sedan on I-45, though the Texas Supreme Court later reversed on procedural grounds and remanded for a new trial.
Related product liability verdicts
Sullivan Papain was among the firms representing New York State against Philip Morris, R.J. Reynolds, Brown & Williamson, and Lorillard, securing a $25 billion recovery through the 1998 Master Settlement Agreement.
C. Steven Yerrid, the youngest of Florida's 11-lawyer 'Dream Team,' added racketeering and conspiracy charges that tripled the damages ceiling, helping the state secure what was then the largest civil settlement in American history against the tobacco industry.
As co-lead counsel in the federal Roundup multidistrict litigation and the first firm to sue Monsanto in 2015, Weitz and Luxenberg helped negotiate a $10.9 billion settlement resolving approximately 125,000 non-Hodgkin lymphoma claims against Bayer-owned Monsanto.
After fifteen years of litigation and three failed bankruptcy maneuvers by Johnson and Johnson subsidiaries, Ashcraft and Gerel attorneys R. Bryant McCulley and Michelle Parfitt helped negotiate a global, uncapped settlement of at least $5.5 billion covering approximately 76,000 ovarian-cancer claims.